An embryo biopsy is when one of our highly skilled embryologists removes a small number of cells from the outer layer of a five or six-day-old embryo. At this stage, the embryo is called a blastocyst, so you might have heard it referred to as a blastocyst biopsy instead. Embryo Biopsies are an essential procedure in our pre-implantation genetic testing procedures.
Individuals or couples at risk of passing on an inherited disease to their children.
Yes, however, there are certain criteria that have to be met to be eligible for NHS funding for PGD treatment. CARE can only accept referrals from a UK Genetic Service. If you think you may be eligible please contact your genetic service directly if you and your family are known to them, or request a referral to Genetics from your GP.
Yes, providing you have a confirmed genetic change that has a risk of being passed to your child then you can request treatment privately. Please contact us.
In the UK, PGD is licensed by the HFEA to ensure that treatment is appropriate.
Some of these conditions include:
A full list is available on the HFEA website.
No.
A licence must be granted by the HFEA in order for PGD to be available for the specific genetic condition. CARE Fertility can apply to the HFEA on your behalf. If you would like further information regarding this process please call Rebecca Jones on 0115 852 8100.
The cost of PGT-M is approximately £9,000 - £10,500 and is divided in to two parts:
OR
Please see our fee schedules for a full breakdown of costs.
The accuracy can vary but for most couples our diagnostic laboratory quote an accuracy of greater the 95% to accommodate all types of conditions.
PGT-M is a relatively new technique. Several studies have been carried out which have concluded that there do not appear to be any major side effects to the treatment. Studies are ongoing following up patients and babies born from PGT-M.
If you have a genetic condition, there is a risk that some of your embryos will be affected. Therefore, to increase your chances of success we need a number of high quality embryos to analyse to identify those free from the genetic condition.
If you are considering PGT-M treatment with a clinic in the UK, the condition must be licensed by the HFEA. if you are unsure if this is the case then please contact our PGT-M co-ordinator Rebecca Jones, on 0115 852 8100 who will be able to advise you further.
Click for more information on PGT-M, or contact CARE.
No. In the UK it is not legal to use PGT-A to select the sex of the embryo for social reasons.
PGT-A is a screening technique that allows us to examine your developing embryos for chromosomal abnormalities prior to embryo transfer.
No. PGT-A is not a test to identify the risk of a specific genetic or inherited disease. That test is PGT-M.
PGT-A is a screening technique that allows us to examine your developing embryos for chromosomal abnormalities prior to embryo transfer.
Click for HFEA information on treatment add-ons and the risks of PGT-A, or contact CARE.
If you would like more information on any of our genomic services then please contact us.
Or if you would like to book an initial consultation you can complete the self referral form online.